Phase I MD Anderson study shows YAP/TEAD inhibitor VT3989 is well tolerated and shows antitumor activity in advanced mesothelioma and NF2-mutant cancers

Elbert Kuo joins Baptist MD Anderson to lead the Division of Surgery

Elbert Y. Kuo, a thoracic surgeon who specializes in minimally invasive techniques, has joined Baptist MD Anderson Cancer Center as head of the Division of Surgery and surgeon-in-chief.

July 18, 2025

Vol.51 No.28

Clinical Roundup

Nivolumab + relatlimab improve survival in advanced melanoma, MD Anderson study shows

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage 3 melanoma remained alive, according to new results from a study led by researchers at the University of Texas MD Anderson Cancer Center.

July 18, 2025

Vol.51 No.28

Clinical

How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest

The windows down the hall from the operating room scrub sinks at MD Anderson Cancer Center look out at the tower of Texas Children’s Hospital.

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 chimeric antigen receptor T cell therapy.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Children’s Research Institute scientists uncover novel mechanism that helps tumors withstand stress

Scientists have discovered tumors can tap a nontraditional pathway to acquire lipoproteins—molecules that transport fat in blood—which enriches cancer cells with an antioxidant shield to survive stress, according to new research from Children’s Medical Center Research Institute at UT Southwestern published in Nature.

June 13, 2025

Vol.51 No.23

Clinical Roundup

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.

June 06, 2025

Vol.51 No.22

Phase I MD Anderson study shows YAP/TEAD inhibitor VT3989 is well tolerated and shows antitumor activity in advanced mesothelioma and NF2-mutant cancers

YOU MAY BE INTERESTED IN

Elbert Kuo joins Baptist MD Anderson to lead the Division of Surgery

Nivolumab + relatlimab improve survival in advanced melanoma, MD Anderson study shows

How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

Children’s Research Institute scientists uncover novel mechanism that helps tumors withstand stress

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

Renew today!

Subscriber content

Never miss an issue!

Login